Literature DB >> 7873706

The pharmacology of human blood vessels in vivo.

D J Webb1.   

Abstract

Forearm plethysmography coupled with brachial artery drug administration and the Aellig technique in hand veins coupled with local venous drug administration are both extremely powerful tools, now widely available to the clinical pharmacologist. These techniques allow precise assessment of drug effects on vascular smooth muscle in vivo, without the confounding influences of drug effects on other organs or activation of neurohumoral reflexes. These local techniques allow the direct study of human vascular physiology, pharmacology, and pathophysiology in vivo in humans. In addition, they can form an important part of the early clinical development programme for new cardiovascular drugs, including drugs affecting the renin-angiotensin system and the sympathetic nervous system, as well as the novel agents arising from research on the vascular endothelium. Given the power of these techniques, it is important to consider where studies in patient volunteers might answer particular questions better than experiments in animal models of disease.

Entities:  

Mesh:

Year:  1995        PMID: 7873706     DOI: 10.1159/000159072

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  19 in total

1.  Ursodeoxycholic acid and endothelial-dependent, nitric oxide-independent vasodilatation of forearm resistance arteries in patients with coronary heart disease.

Authors:  J Sinisalo; H Vanhanen; P Pajunen; H Vapaatalo; M S Nieminen
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

2.  Endothelial venodilator response in carriers of genetic polymorphisms involved in NO synthesis and degradation.

Authors:  Ruth Fricker; Christiane Hesse; Johanna Weiss; Yorki Tayrouz; Michael M Hoffmann; Kristina Unnebrink; Ulrich Mansmann; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

3.  Responses to endothelin-1 in patients with advanced cirrhosis before and after liver transplantation.

Authors:  A Helmy
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

4.  Effects of different congestion pressures on the diameter of the dorsal hand vein and on its apparent sensitivity to noradrenaline.

Authors:  A H Abdelmawla; R W Langley; E Szabadi; C M Bradshaw
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-02       Impact factor: 3.000

5.  Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo.

Authors:  D E Newby; F N Witherow; R A Wright; P Bloomfield; C A Ludlam; N A Boon; K A A Fox; D J Webb
Journal:  Heart       Date:  2002-01       Impact factor: 5.994

6.  Vasodilator effects of the endothelin ET receptor selective antagonist BMS-193884 in healthy men.

Authors:  Neeraj Dhaun; Fiona E Strachan; David E Newby; Neil R Johnston; Neville F Ford; Janis L Hammett; Maria Palmisano; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

7.  Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites.

Authors:  J W Ferguson; A R Dover; S Chia; N L M Cruden; P C Hayes; D E Newby
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

8.  Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure.

Authors:  J P Noon; B R Walker; D J Webb; A C Shore; D W Holton; H V Edwards; G C Watt
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

Review 9.  Atherosclerosis, cigarette smoking, and endogenous fibrinolysis: is there a direct link?

Authors:  Stanley Chia; David E Newby
Journal:  Curr Atheroscler Rep       Date:  2002-03       Impact factor: 5.113

10.  Reproducibility of forearm vasodilator response to intra-arterial infusion of calcitonin gene-related peptide assessed by venous occlusion plethysmography.

Authors:  Floris H M Vanmolkot; Jan N J M de Hoon
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.